1. Control arm doing as well as study arm.
- Lots of historical data showing between 2 and 5 months average, so why would the control suddenly be so good?
2. Study design flawed.
- Design approved by fda.
3. Sudden, heinous toxic side effects.
- No heinous side effects to date. HA makes the chemo not so nasty, hence more can be given.
4. Data from Eastern Europe not robust.
- The same being used as used by Abraxis.
5. Over optimistic management.
- ACL seem to have a good knowledge base now, with lots of experience.
- Forums
- ASX - By Stock
- what could go wrong?
1. Control arm doing as well as study arm.- Lots of historical...
-
-
- There are more pages in this discussion • 139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable